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Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that exists in living systems, and it is a major component of
the extracellular matrix. The hyaluronic acid receptor CD44 is found at low levels on the surface of epithelial, haematopoietic, and
neuronal cells and is overexpressed inmany cancer cells particularly in tumour initiating cells. HA has been therefore used as ligand
attached to HA-lipid-based nanovectors for the active targeting of small or large active molecules for the treatment of cancer. This
paper describes the different approaches employed for the preparation, characterization, and evaluation of these potent delivery
systems.
1. CD44 Receptor
CD44 (cluster of differentiation 44) is a widely expressed cell
surface hyaluronan receptor which consists in a single chain
transmembrane glycoprotein with a size that varies between
80 and 200 kDa. It is moreover an acidic molecule with an
isoelectric point between 4.2 and 5.8 [1]. CD44 receptor
belongs to the family of cell adhesion molecules (CAMs)
together with selectins, integrins, and cadherins. The CAMs
control cell behavior by mediating contact between cells or
between cells and the extracellular matrix and are essential
for maintaining tissue integrity. Because of these important
functions, they are also involved in pathological conditions
including tumor progression and metastasis [2]. It is well
known that various tumors, for example, epithelial, ovarian,
colon, stomach, and acute leukemia, overexpress CD44 [3].
CD44 comprise a family of glycoproteins encoded by
a single gene located on the short arm of chromosome
11 and composed of 20 exons [4]. Extensive alternative
splicing generatesmultiple variant isoforms of CD44 receptor
denoted as CD44v. The most abundant standard isoform
of human CD44 protein is the smallest isoform that lacks
any variant exons, designated CD44s, but some epithelial
cells also express a larger isoform called CD44E [5]. The
expression of CD44 isoforms containing combinations of
the other variant exons is far more restricted in normal
tissues. In particular, CD44s is abundantly expressed by both
normal and cancer cells, whereas the variant CD44 isoforms
(CD44v), that contain a variable number of exon insertions
(v1–v10) at the proximal plasma membrane external region,
are expressed mostly by cancer cells.
CD44 is endogenously expressed at low levels on various
cell types of normal tissues [6, 7] but requires activation
before binding to hyaluronan [8–11].
The CD44 structure of normal cells is distinct from that
of cancer cells because pathological conditions promote alter-
nate splicing and posttranslational modifications to produce
diversified CD44 molecules with increased tumorigenicity
[22, 23].
The effect of native hyaluronan as well as of the catabolic
enzymes and the degradation products of thismacromolecule
on tumor progression is complex. Moreover, the amount
of intratumoral hyaluronan also varies depending on the
cell type and on the degree of tumor cell differentiation.
There are some good reviews that describe the association
of CD44 receptor with human cancer cells and underline the
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Figure 1: Chemical structure of HA.
receptor’s role in the progression of the disease [10, 24]; thus
the overexpression of CD44 could be a good tool in drug
delivery approaches using the receptor as an anchor to attach,
through a ligand, prodrugs or nanomedicine-based delivery
systems to increase the efficiency of anticancer drugs [25].
2. Hyaluronic Acid
Hyaluronic acid (hyaluronan, HA) is a nonsulfated gly-
cosaminoglycan polymer. It is ubiquitous, being the main
component of extracellular matrix [26]. HA is composed
of disaccharide units of D-glucuronic acid and N-acetyl-D-
glucosamine linked together through alternating𝛽
1,3
and 𝛽
1,4
glycosidic bonds (Figure 1). HA is a biodegradable polymer
with a molecular weight of 106–107Da that is biocompatible,
nontoxic, hydrophilic, and nonimmunogenic [27]. Moreover,
HA molecules have a number of sites suitable for chemi-
cal modification such as hydroxyl, carboxyl, and 𝑁-acetyl
groups.
In adult tissues such as the vitreous, synovial fluid and
dermis, hyaluronan plays an extracellular, structural role
that depends on its hydrodynamic properties as well as on
its interactions with other extracellular matrix components.
However, it is also concentrated in regions of high cell
division and invasion (during embryonic morphogenesis,
inflammation, wound repair, and cancer). Hyaluronic acid is
thus also involved in tumorigenesis, and its role is complex
anddepends on various factors such as, for example itsmolec-
ular weight. In fact lower molecular weight HA (10–100 kDa)
stimulates angiogenesis but high molecular weight hyaluro-
nan (>1,000 kDa) is inhibitory [28–30]. High amount of HA
production usually promotes tumor progression, but it was
observed that extremely high levels of hyaluronan production
can be inhibitory [31]. As also reported, tumor progression
is often correlated with both hyaluronan and hyaluronidase
levels in human cancers [32]. These considerations led to the
hypothesis that the turnover of HA is strictly involved in the
promotion of tumor progression by HA [33–35].
In addition to its principal and previously described
receptor, CD44, HA also interacts with other cell sur-
face receptors such as RHAMM (receptor for hyaluronan-
mediated motility, CD168), ICAM-1 (intracellular adhesion
molecule-1), TLR-4 (toll-like receptor-4), HARE (HA recep-
tor for endocytosis), and LYVE-1 (lymphatic vessel endocytic
receptor).
The mechanism of HA-CD44 binding is still not fully
understood, but it has been reported that the CD44 receptor
contains the specific binding domain for HA, which consists
of 160 amino acid residues. The binding affinity of CD44
to HA was found to be dependent on the size of HA
oligomers. In fact, hexamer and decamer are considered to
be the minimum size able to bind to CD44 while larger
oligomers (20) have higher binding affinity because of their
multiple interactions with more than one CD44 receptor
simultaneously [3, 8, 36, 37].
It has also been reported that all the CD44 isoforms have
uniform affinity for HA [38]; therefore HA can be used as
vector for the active targeting of anticancer drugs. Different
strategies have been exploited with interesting results, for
example, in the preparation of bioconjugates obtained by
covalently linkingHA to a cytotoxic drug such as, for example
paclitaxel [39, 40] or doxorubicin [41, 42].These topics are out
of the scope of this paper where only strategies consisting in
the design of HA decorated nanosystems will be discussed in
depth.
3. Chemical Conjugation of HA to
Lipid-Based Nanocarriers
Different approaches can be used to bind HA to the lipid-
based nanocarriers, depending on the molecular weight of
the HA as well as on the need to start from preformed
nanocarriers or from pure lipids that will be then used to
prepare particles.
HA binding to preformed nanocarriers was the firstly
used method [43] and offers the advantage to conjugate the
HA only on the external surface of the particle. Of course,
this approach makes difficult the control of the density of
attachment of HA on the carrier surface. Moreover, the
lower specificity of the linkage, due to the possibility to bind
different amino groups, results in a consequent multipoint
attachment of the polymer on the nanocarrier that is then
difficult to characterize.
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Alternatively, HA can be previously conjugated to a
pure lipid and then added in the lipid mixture during the
preparation of the nanoparticles. This procedure permits the
introduction of a controlled amount of HA on nanocarriers,
but could require a more elaborated synthetic method.
3.1. HA Binding to Preformed Nanocarrier. High molecular
weight (HMW) HA was attached to the surface of preformed
liposomes through amidation reaction between the aminore-
active group of a lipid on the liposome surface, generally
a phosphatidylethanolamine (PE), and HA glucuronic car-
boxylate (Figure 2) [13, 14, 43]. The amidation reaction was
performedpreactivatingHAby incubationwith the 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) condensing
agent in acidic medium and then adding the activated HA to
the nanocarrier suspension in a basic medium. Elimination
of the excess of reagent and reaction byproducts was obtained
by centrifugation and repeated washing.
3.2. Preparation of HA-PE Preformed Conjugates. HA conju-
gation to the lipid before nanocarrier preparation was carried
out with both high and low molecular weight (LMW) poly-
mers [12, 19]. In all cases, HA reacted with an aminoreactive
group present on the lipid that was PE, also in this case
(Figure 2). Two different conjugation methods have been
proposed depending on the HA molecular weight. Eliaz
and Szoka attached a mixture of oligosaccharide HA to
PE by reductive amination using sodium cyanoborohydride
as reducing agent [12]. Reductive amination is a chemical
reaction widely used in polysaccharide conjugation and
consists in two steps. In the first step, the aldehydic group
of the terminal residue of HA, generated by opening the
sugar ring, reacts, in acidic medium, with the amino group
of PE forming the unstable imine.Then, the imine is reduced
in the presence of a reducing agent to a secondary amine
leading to the formation of the conjugate. An improvement
of this reaction was proposed by the same group in 2006 [44].
The authors developed a methodology for the preparation of
aldehyde functionalized HA and reported that the reductive
amidination with this derivative is more efficient than that
performed using the classical approach consisting in the
reaction at the sugar reducing end.
In these reactions involving LMW-HA, only one PE
molecule was linked to the polymer. Both kinds of conjugates
were purified by silica column chromatography, and the latter
was characterized by MALDI and 1HNMR.
HMW-HA-dioleoylphosphatidylethanolamine (DOPE)
conjugate was prepared by EDC-mediated amidation
reaction [19]. In this conjugate the DOPE amino group
is randomly linked to the carboxylic residues of HA. The
conjugate was purified by ultrafiltration and dialysis and
its purity was assessed by capillary electrophoresis [20].
This conjugate was introduced into cationic lipids during
liposome formation [19–21].
A similar synthetic approach was used by Toriyabe
et al. [45] for the preparation of a conjugate between HA
and stearylamine (HA-SA conjugate). SA was linked via an
amide linkage using EDC and NHS as coupling agents; then
+
HA
(a)
+
PE HA-PE preformed 
 conjugate
HA
(b)
Figure 2: Strategies to prepare HA-coated nanocarriers. A
schematic representation. (a) HA binding to preformed nanocarrier.
Amidation reaction betweenHA-carboxyl group and aminoreactive
group of lipid on the liposome surface. (b) Synthesis of HA-
PE conjugates and following preparation of HA-coated lipid
nanocarrier for postinsertion. (i) Reductive amination at the HA
reducing end. (ii) Amidation reaction between HA-carboxyl group
and aminoreactive group of lipid (PE).
the solution of conjugate was added and incubated to the
liposome suspension.
Recently Cho et al. described the preparation of an
amphiphilic polymer obtained conjugating HA oligomers
to a cellular component, ceramide (CE). To obtain HA-CE
conjugate, HA was first activated by reaction with tetra-n-
butylammoniumhydroxide (HA-TBA), and CE was previ-
ously modified by esterification reaction with chloromethyl-
benzoyl chloride, used as linker. Then linker CE was conju-
gated to HA-TBA by ether bond formation [17].
4. Lipid-Based Nanocarriers for Targeting of
CD44-Rich Cells
First evidence of powerful delivery of chemotherapeutics
to cancer cells by HA-modified liposomes was provided
by the group of Eliaz and Szoka [12] (Table 1). In this
study, a low LMW-HA was bound onto the liposome sur-
face. The authors demonstrated B16F10 cells expressing high
levels of CD44, an avid cell-liposome binding followed by
internalization in a temperature-dependent manner. Lower
uptake was found in cells expressing low levels of CD44
(CV-1). B16F10 cell association of the unilamellar vesicles
was found to depend critically on the density of HA on
liposome surface. These findings were observed after expos-
ing cells to HA-modified liposomes in both transient (3 h
and replacement with fresh cell medium) and continuous
conditions for periods going up to 24 h [12]. Moreover, for
given amounts of intracellular-delivered chemotherapeutic
agent, namely, doxorubicin (DOX), the encapsulated form
was more efficient in killing B16F10 cells than the free form
[12]. Due to the enhanced potency of DOX encapsulated
into HA-modified liposomes, it was hypothesized that the
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Table 1: Examples of HA-decorated lipid-based nanocarriers for targeting of CD44.
Carrier Drug HA Main findings Reference
Liposomes DOX LMW-HA
Avid cell-liposome binding followed by internalization in cells
overexpressing CD44.
Higher cytotoxicity compared with free drug on
CD44-overexpressing cells.
[12]
Liposomes MMCDOX HMW-HA
Higher affinity of HMW-HA to bind the CD44 receptors,
compared to hyaluronan fragments.
Long-term circulation of HMW-HA liposomes.
HMW-HA can act as cryoprotectant, thus allowing liposome
lyophilization.
Loading into the HA-modified liposomes generates a 100-fold
increase in drug potency in tumor cells overexpressing CD44
receptors.
Higher drug accumulation in tumor, compared to free drug or
drug in unmodified liposomes.
[13, 14]
Self-assembled lipid
nanoparticles PTX HMW-HA
Reduced PTX accumulation in liver and spleen and increased
drug accumulation in the tumor, compared to Taxol.
Prolonged PTX half-life.
Reduced PTX toxicity.
[15]
HA-coated
nanostructured lipid
carriers
PTX HMW-HA
More effective than Taxol with fewer side effects.
Prolonged PTX half-life.
Increased PTX accumulation in tumors.
[16]
Self-assembled
nanoparticles DCT LMW-HA
Enhanced intracellular DCT uptake in the
CD44-overexpressing cell lines.
MDR-overcoming effects.
In vivo specific CD44-mediated tumor targeting.
[17]
PEGylated self-assembled
nanoparticles DOX
Improved retention time in the bloodstream and nanoparticle
accumulation at the tumor site.
PEGylation resulted in prolonged nanoparticle circulation and
reduced DOX clearance rate.
Higher in vivo antitumor efficacy in the tumor xenograft
mouse model in comparison to non-PEGylated nanoparticles
and DOX alone.
[18]
Cationic liposomes DNA andsiRNA HMW-HA
The presence of HA-DOPE lipid conjugate in the liposome
composition did not affect the lipoplex formation.
Increased nucleic acid protection against enzymatic
degradation.
Increased the level of transfection on CD44-highly expressing
cells.
[19–21]
Nanoparticles — Different molecularweights No induction of complement activation. [18]
drug reaches a critical compartment more efficiently, when
compared with the free form. In particular, the authors
hypothesized that an uptake of the delivery system via a non-
clathrin-coated endosome, as already reported in the case
of hyaluronan catabolism, could occur [46]. This hypothesis
was recently confirmed by our group after incubating HA-
modified cationic liposomes with CD44-expressing A549
cells with different endocytosis inhibitors [20]. It was found
that the transfection efficiency of HA-modified cationic lipo-
somes was not affected by a clathrin-mediated endocytosis
inhibitor, while it was significantly decreased by inhibitors of
caveolae-mediated endocytosis, demonstrating that the latter
is the main endocytosis pathway of HA-bearing lipoplexes. It
is worthy of note that in the studies of Eliaz et al. [47] and
Dufay¨ Wojcicki et al. [20] an LMW and an HMW-HA were
used, respectively, although a similar endocytotic pathway
can be reasonably hypothesized.
The targeting of cancer cells using HMW-HA bound to
liposomes was firstly demonstrated by Peer and Margalit
[13, 14]. HMW-HA should offer advantages such as to bind
the CD44 receptors with a higher affinity than hyaluronan
fragments, to provide long-term circulation through its many
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hydroxyl residues, and to allow liposome lyophilization, due
to the properties of HA to act as a cryoprotectant [48].
In particular, in an in vivo study, HA-modified liposomes
resulted in long-circulating species, over a time frame at
least equal to those reported for PEG-coated liposomes [13].
Mitomycin C (MMC), a chemotherapeutic agent used in
different form of tumors but also characterized by severe
side effects, was encapsulated into HA-modified liposomes
and tested in vitro and in two experimental models of lung
metastases. The in vitro studies showed that loading into
the HA-modified liposomes generates a 100-fold increase in
MMC potency in tumor cells that overexpress hyaluronan
receptors, but not in cells with poor expression of these
receptors. Moreover, when using HA-modified liposomes,
MMC accumulated in the tumor 30-fold higher than when
the drug was administered in free form and 4-fold higher
than when delivered via unmodified liposomes. Interest-
ingly, liver uptake was significantly reduced when the drug
was delivered via the HA-modified liposomes that should
contribute to reducing the subacute toxicity associated with
MMC administered as free drug [13]. It is worthy of note
that, in the case of MMC free or encapsulated in unmodified
liposomes, tumor size, metastatic burden, and survival time
were not much different than those observed in untreated
mice. High positive responses were only reported in the case
of mice treated with MMC HA-modified liposomes. Similar
results were obtained from different experimental model
of tumors with HA-modified liposomes, but replacing the
MMC with DOX, thus demonstrating that the targeting is
carrier-specific, rather than drug-specific [14]. In this study,
the HA-modified formulation was compared to free DOX,
DOX encapsulated in unmodified liposomes, and pegylated
liposomes (Doxil). Drug accumulation in tumor-bearing
lungs, as well as key indicators of therapeutic responses
such as tumor progression, metastatic burden, and survival,
was superior in animals receiving DOX-loaded HA-modified
liposomes, compared to the controls.
HA-modified lipid-based nanoparticles encapsulating
paclitaxel (PXT) were also proposed. PXT is a chemothera-
peutic agent largely used in the treatment of solid tumors.
However, its poor water solubility as well as the lack of
selective delivery approach represents important clinical lim-
itations. In vivo evidence of CD44 targeting by HA-modified
lipid-based nanoparticles was also obtained by encapsulating
paclitaxel (PXT) into self-assembled lipid nanoparticle-like
“clusters” [15]. Thus, HA-coated PXT-encapsulating clusters
were administered in an experimental mice model of colon
adenocarcinoma, and their antitumor effect, as well as the
toxicity, was compared with that of FDA approved PXT
formulations, namely, Taxol (PTX solubilized in the deter-
gent Cremophor EL and in ethanol) and Abraxane (PXT
encapsulated into albumin nanoparticles). Safety of the new
HA-targeted formulation was demonstrated by any change
in blood levels of enzymes released from the liver, namely,
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST), respectively, regarded as reliable indicators
of liver tissue damage and, more generally, systemic tissue
damage. This effect was not associated with any change in
body weight. On the contrary, multiple i.v. administrations
of Taxol resulted in changes of body weight and release of
high amounts of liver enzymes [15]. Moreover, when using
Taxol, PXT was eliminated from the circulation within less
than 1 h after i.v. injection, while PTX, administered within
HA-modified lipid clusters, was still circulating even 24 h
after i.v. injection. These findings still support the hypothesis
that HMW-HA, when used as targetingmoieties, also confers
stealth properties on the nanoparticles. Interestingly, the HA-
modified nanoparticles reduced PTX liver and spleen accu-
mulation by almost 2-fold and increased PTX accumulation
in the tumor by 10-fold compared to Taxol. Finally, tumor
progression was exponential in the case of 5mg/Kg body
Taxol or Abraxane, while it was arrested at the same dose of
PXT administered in HA-modified lipid clusters. This effect
was also obtained with 20mg/Kg body of Taxol, although it
was associated with a significant loss of body weight indi-
cating global toxicity [15]. Recently, Yang et al. proposed the
preparation of HA-coated nanostructured lipid carriers (HA-
NLCs) for tumor targeting via electrostatic attraction [16]. In
this approach, cationic NLCs loaded with PTXwere prepared
by melt emulsion technology, followed by coating with HA
(300 kDa); the process of electrostatic attraction was simple
and controllable, and no chemical reagents were needed.The
in vitro cytotoxicity and in vivo antitumoral activity studies
showed that HA-PTX-NLCs were more effective than Taxol
with fewer side effects. HA-NCL also prolonged the blood
circulation time of PTX and increased its accumulation in
tumors.
HA-modified nanoparticles have been proposed to over-
come clinical limits of chemotherapeutics, such as Docetaxel
(DCT). DTC is a semisynthetic taxane derivative very effec-
tive against different tumors, but its clinical use causes several
side effects and other limitations regarding the appearance
of multidrug resistance (MDR) and its insolubility. Recently
Cho et al. described the preparation of HA-ceramide (CE)
self-assembled nanoparticles for DCT and DOX active tar-
geting [17, 49]. The in vitro cellular uptake studies showed
that nanoparticles enhanced intracellular DCT uptake in the
CD44-overexpressing cell lines MCF-7. MDR-overcoming
effects of DCT nanoparticles were observed in cytotoxicity
test in CD44-positive MCF-7 breast cancer cells resistant to
doxorubicin. The in vivo tumor targetability was evaluated
using a noninvasive fluorescence imaging system in the same
cells xenografted in a mouse model. To assess the uptake
mechanismby a competitive inhibition assay, CD44 receptors
were blocked with preinjection of high doses of HA. The
fluorescence signal in the HA preinjected animal group was
lower than that in no preinjection group for 24 h, indicating
a probable reduction in nanoparticle uptake due to the
blocking of CD44. The real-time imaging data showed that
the fluorescent signal increased for the first 6 h and was
maintained for 1 day. Then the tumors were dissected 24 h
following injection, and the observed fluorescence intensity
of HA pre-injection group was only 43.9% of the no preinjec-
tion group.
The same research team described the preparation of
DOX-loaded, self-assembled, HA-CE-PEG-based nano-
particles [18]. In vitro tests were performed on two different
cell lines with different CD44 expression: NIH3T3 (mouse
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embryonic fibroblast cells, CD44-negative) and SCC7
(mouse squamous cell carcinoma cells, CD44-positive). The
cytotoxicity studies showed that HA-CE-based nanoparticles
can be used as vehicle without important toxicity. The
cellular uptake efficacy of DOX from nanoparticles via
HA and CD44 interaction was demonstrated by confocal
microscopy analysis. In vivo studies on SCC7 tumor
xenograft mouse model showed improved retention time
in the bloodstream and nanoparticle accumulation at the
tumor site. The pharmacokinetics evaluation confirmed that
PEGylation resulted in prolonged nanoparticle circulation
and reduced DOX clearance rate. Improved half-life of DOX,
when formulated as HA-CE-PEG nanoparticles, led to higher
in vivo antitumor efficacy in the tumor xenograft mouse
model in comparison to non-PEGylated nanoparticles and
DOX alone.
HA was also used to increase transfection efficiency of
cationic liposomes. Plasmid DNA and siRNA were success-
fully delivered to CD44-expressing cancer cells with this
approach [19, 21]. The use of a lipid conjugate HA-DOPE
into the liposome composition did not affect the lipoplex
formation upon liposome mixing with DNA [19] or siRNA
[21]. On the contrary the lipoplex zeta potential was strongly
affected shifting from a positive to a negative value. This
was consistent with the presence of HA at lipoplex surface.
Moreover, the presence of HA in the liposome formulation
led to increased nucleic acid protection from degradation
against DNase I or RNAse V1, probably because the HMW-
HA and cationic lipids prevent access of these enzymes to
the whole colloidal system [19, 21]. The presence of HA-
DOPE did not modify the in vitro cytotoxicity, on the MDA-
MB-231 and MCF-7 breast cancer cell lines, characterized
by high and low expressions of CD44, respectively. On
the contrary, the use of HA strongly reduced the cytotoxic
profile of DOTAP/DOPE liposomes in combination with
siRNA on A549 CD44-expressing cells [21]. This effect was
attributed to the endogenous nature of HA that should be
biocompatible and, when located on the lipoplex surface,
might avoid the direct contact of the cationic liposome with
the negatively charged cell surface and hence reduce its
cytotoxic potential. Finally, HA-DOPE increased the level of
transfection on CD44-highly expressing cells (MDA-MB-231
or A549) compared to the cells expressing low levels of CD44
(MCF-7 or Calu-3). The involvement of the CD44 receptors
was confirmed by using anti-CD44 Hermes-1 antibody that
highly inhibited transfection efficiency; this effect was not
observed by nonspecific anti-ErbB2 antibody [19, 20].
HA-coated cationic liposomes were also prepared using
anHA-stearylamine (SA) conjugate, and their ability to reach
liver endothelial cells was evaluated [45]. The pharmacoki-
netics and biodistribution studies on HA-SA modified lipo-
somes showed that liver accumulation was higher than the
corresponding value for nonmodified liposomes at every time
point and increased depending on the extent of modification
of HA-SA. On the contrary, if free HA was introduced
on liposomes surface, via electrostatic interactions, liver
accumulation decreased indicating that HA alone did not
fully function as targeting ligand. From confocal microscopy
analysis, HA-SA modified liposomes accumulated along the
blood vessels to a greater extent than nonmodified liposomes,
suggesting that the HA-coated liposomes are distributed
within endothelial cells in the liver.
Recently, the complement activation capacity of HA
nanoparticles has been investigated [20, 50]. Complement
activation is an important aspect to consider since it may
initiate adverse reactions among sensitive individuals and
could represent an obstacle for the clinical application of HA-
decorated nanovectors. Mizrahy et al. evaluated the level of
the terminal complement pathway activation markers C5a
and SC5b-9 by ELISA on a panel of nanoparticles deco-
rated with HA of different molecular weights (ranging from
6.4 kDa to 1500 kDa). In these experiments, no induction of
complement activation was observed, and the marker levels
remained comparable with the baseline value [50]. Dufay¨
Wojcicki et al. [20] evaluated the behavior of HA lipoplexes
made with increasing lipids : DNA ratio (2, 4, and 6) and the
activation of a protein of complement cascade, the protein
C3, were determined by 2D immunoelectrophoresis. Low
activation of complement was observed in all the formula-
tions although lipoplexes containing HA with lipids, DNA
ratios of 4 and 6, give higher values than the respective
nonhyaluronate samples [20]. These data suggest that HA-
coated nanosystems could be an interesting alternative to
PEG grafted particles since the latter were shown to activate
complement after intravenous administration [51].
The impact of HA size and density of HA-grafted
nanoparticles on affinity toward CD44 was evaluated in
a systematic manner [50, 52]. Qhattal and Liu prepared
liposomes decorated with HA of both low and high molec-
ular weights (5–8, 10–12, 175–350, and 1600 kDa) and with
different degree of grafting density. They performed in vitro
studies (fluorescence microscopy analysis, flow cytometric
analysis, and competitive binding experiments) and stated
that cellular targeting efficiency of HA liposomes depends on
HAmolecular weight, grafting density, and cell surface CD44
receptor density. In particular, the HA liposomes binding and
internalization increased with increasing polymer molecular
weight and/or the grafting density [52]. A small library of
HA-coated nanoparticles distinguished by the size of their
surface HA was also described [50]. The authors used HA
of 5 different molecular weights (6.4 kDa, 31 kDa, 132 kDa,
700 kDa, and 1500 kDa) and evaluated the nanoparticles
interaction with CD44 receptor through surface plasmon
resonance analysis. Also in this case, the affinity towards
CD44 was low for LMW-HA and increased with the polymer
molecular weight [50].
5. Conclusions
HA represents a promising opportunity to develop new can-
cer therapies. A growing number of scientific works explored
the possibility to target cancer cells overexpressing CD44
receptor by usingHA-modified vectors. HA is biocompatible,
biodegradable, nontoxic and noninflammatory. Moreover, it
can easily undergo chemical modifications and conjugates
with drugs or other ligands. HA targeting of cancer cells over-
expressing CD44 receptor has been largely demonstrated. In
Journal of Drug Delivery 7
addition, HA coating has been recently proposed as a safer
alternative to PEG grafting in order to increase the particles’
half-life. The success of this strategy is demonstrated by an
HA conjugate at the moment in clinical trials. A phase III
clinical trial based on a hyaluronic acid-Irinotecan conjugate
is in the recruitment state, and the final data collection is
scheduled for January 2014. The possibility to conjugate HA
to lipid-based nanocarriers, such liposomes that are on long
time in the clinical practice, should open new opportunities
to target cancer cells also with drug that cannot be easily
conjugated to HA. Further studies are certainly needed to
understand the relations between the molecular weight and
“biological” properties of HA, especially in the interaction of
HA-modified nanoparticles with the target.
Moreover, further information on the in vivo distribution
of HA conjugated nanocarries as well as their tumor local-
ization should be useful to design new anticancer therapies
based on CD44 targeting.
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